4 key learnings from Day 1 of EMAS 2017- CHD, Cognition and Breast

1.  Stopping MHT-The International Menopause Society presented on the consequences of stopping MHT, challenging existing beliefs that women should be taken off MHT after they reach the age of 60 or within 5 years of use. IMS believe the key is to personalise all decisions to the patient. They believe women should take MHT as long as they are experiencing treatment benefit and risks have been evaluated.

 

2.  Impact of MHT on CHD-Evidence shows that MHT can be largely beneficial in reducing CHD, however this benefit is dependent both on age and time of initiation of HRT, with the largest benefit being seen in women starting treatment under the age of 60 and within 10 years of the onset of menopause.  

 

3.  Link between MHT and cognition- More clinical data needs to be collected in order to decide if MHT should be indicated for the prevention or treatment of cognitive problems, early data suggests that MHT has a neutral impact on cognition and may even result in reduction in memory problems.

 

4.  Relationship between MHT and the breast-Data shows that in most cases MHT is not associated with an increased risk of breast cancer and has even been shown to reduce mortality from breast cancer as demonstrated by the Finnish Nationwide Study.

 

Day 1 was full of evidence based updates with a range of presenters challenging decisions based on historic WHI study data. As day two approaches, we are excited to see what other developments EMAS has to share with us! Check back tomorrow for more data updates and patient cases.